Stomach flu vaccine shows promise in massive Kids' trial
NCT ID NCT05916326
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large phase 3 trial tested a new norovirus vaccine in 8,000 healthy children aged 6 months to 13 years. The vaccine targets two common norovirus strains (GⅠ.1 and GⅡ.4) that cause severe vomiting and diarrhea. Researchers compared vaccinated kids to those who got a placebo to see if the shot prevents moderate to severe stomach flu.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Norovirus bivalent vaccine (GⅠ.1/GⅡ.4)
- What this could lead to
- If successful, this vaccine could protect children against the most common causes of severe vomiting and diarrhea from norovirus.
- What could go wrong
- This is a completed trial, but results are not yet published. The vaccine may not work against all norovirus strains, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOROVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jingxing County Center for Disease Control and Prevention
Shijiazhuang, Hebei, China
-
Laishui County Center for Disease Control and Prevention
Baoding, Hebei, China
-
Zhao County Center for Disease Control and Prevention
Shijiazhuang, Hebei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.